HCW Biologics Initiates First-In-Human Clinical Trial for HCW9302 in Alopecia Areata Treatment

HCW Biologics has initiated a clinical trial to evaluate HCW9302, an interleukin-2 fusion molecule, for autoimmune diseases. The first patient has been dosed at The Ohio State University Wexner Medical Center. HCW9302 aims to activate and expand regulatory T cells to control excessive inflammation. It has the potential to treat alopecia areata, an autoimmune disease that causes hair loss and affects 160 million people worldwide. HCW Biologics is a clinical-stage biopharmaceutical company focused on developing immunotherapies to extend healthspan by targeting chronic inflammation and disease.